

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 83-232

ADMINISTRATIVE DOCUMENTS

MEMO RECORD		AVOID ERRORS PUT IT IN WRITING		DATE
FROM: MARVIN SEIFE, M.D.		OFFICE		9/10/74
TO: DCR		DIVISION		OSE
SUBJECT: HFD-220		Generic Drug Staff		
SUMMARY				
<p>NDA 83-232 Hydrochlorothiazide 50mg. Tablets Danbury Pharmacal Inc.</p> <p>Additional bioavailability study data as requested by us. Please review.</p> <p>Thank you.</p> <p>/S/</p>				
SIGNATURE			DOCUMENT NUMBER	

MEMO RECORD	AVOID ERRORS PUT IT IN WRITING	DATE 5-14-73
FROM: M Clark MD		OFFICE DES/
TO: DCH		DIVISION
SUBJECT:		
SUMMARY Would you please comment on this protocol? Thank you		
SIGN /S/		DOCUMENT NUMBER 83-232

MEMO RECORD	AVOID ERRORS PUT IT IN WRITING	DATE 4/4/73
FROM: MARVIN SEIFE, M.D.	OFFICE	
TO: DR. J. P. SKELLY	DIVISION	
SUBJECT: BD-220		
SUMMARY DCR		
<p>ANDA 83-232 HYDROCHLOROTHIAZIDE DANBURY</p> <p>Please review the proposed bioavailability protocol. Thank you.</p> <p>/S/ BD-69</p>		
SIGNATURE	DOCUMENT NUMBER	

4/4